Search

Transgender and gender diverse (TGD) people in the United States face high rates of minority stressors, such as social rejection, homelessness, discrimination, and identity-based violence (James et al., 2016). Transgender and gender diverse service members are also exposed to unique military-specific stressors such as discriminatory military policies, combat stress, and military sexual trauma (Tucker et al., 2019). However, little is known about TGD troops' experiences of resilience when navigating stress and trauma exposure during their military service. A transaffirmative participatory research design and interpretative phenomenological analysis (IPA) analytic method were used to explore how troops made sense of their experiences of oppression and resilience. Researchers interviewed TGD service members (

Despite advances in precision medicine, the clinical prospects for patients with ovarian and uterine cancers have not substantially improved. Here, we analyzed genome-scale CRISPR-Cas9 loss-of-function screens across 851 human cancer cell lines and found that frequent overexpression of SLC34A2-encoding a phosphate importer-is correlated with sensitivity to loss of the phosphate exporter XPR1, both in vitro and in vivo. In patient-derived tumor samples, we observed frequent PAX8-dependent overexpression of SLC34A2, XPR1 copy number amplifications and XPR1 messenger RNA overexpression. Mechanistically, in SLC34A2-high cancer cell lines, genetic or pharmacologic inhibition of XPR1-dependent phosphate efflux leads to the toxic accumulation of intracellular phosphate. Finally, we show that XPR1 requires the novel partner protein KIDINS220 for proper cellular localization and activity, and that disruption of this protein complex results in acidic "vacuolar" structures preceding cell death. These data point to the XPR1-KIDINS220 complex and phosphate dysregulation as a therapeutic vulnerability in ovarian cancer.